Text Size

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

This study has been completed.
Sponsor:
Collaborator:
Genzyme
Information provided by (Responsible Party):
Dr. Chadi Nabhan, Oncology Specialists, S.C.
ClinicalTrials.gov Identifier:
NCT00156013
First received: September 8, 2005
Last updated: June 4, 2012
Last verified: June 2012
History of Changes
Results First Received: October 6, 2011  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Intervention: Drug: CLOFARABINE

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Clofarabine Clofarabine 4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles.

Participant Flow:   Overall Study
    Clofarabine  
STARTED     33  
COMPLETED     31  
NOT COMPLETED     2  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Clofarabine Clofarabine 4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles.

Baseline Measures
    Clofarabine  
Number of Participants  
[units: participants]
 		  33  
Age  
[units: participants]
 		 
<=18 years     0  
Between 18 and 65 years     0  
>=65 years     33  
Age  
[units: years]
Mean ( Full Range ) 		  69  
  ( 27 to 85 )  
Gender  
[units: participants]
 		 
Female     19  
Male     14  
Region of Enrollment  
[units: participants]
 		 
United States     33  



  Outcome Measures

1.  Primary:   Phase I Maximum Tolerated Dose   [ Time Frame: days 1 -28, maximum 6 cycles ]
  Show Outcome Measure 1

2.  Primary:   Phase II Overall Response   [ Time Frame: 5 years ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

3.  Secondary:   Time to Treatment Failure   [ Time Frame: 5 years ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   Toxicity   [ Time Frame: 5 years ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   Yes


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Chadi Nabhan, MD
Organization: Oncology Specialists
phone: 847-268-8200
e-mail: cnabhan@oncmed.net


No publications provided by Oncology Specialists, S.C.

Publications automatically indexed to this study:


Responsible Party: Dr. Chadi Nabhan, Oncology Specialists, S.C.
ClinicalTrials.gov Identifier: NCT00156013     History of Changes
Obsolete Identifiers: NCT00305721
Other Study ID Numbers: 1066306 (0408)
Study First Received: September 8, 2005
Results First Received: October 6, 2011
Last Updated: June 4, 2012
Health Authority: United States: Institutional Review Board